Diurnal Group plc (DNL) Ordinary 5p
Share news, reports & tips
2 December 2019 13:19
(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of...
3 July 2019 10:38
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Wednesday that an application for market authorisation for \'Alkindi\' - hydrocortisone granules in capsules for...
28 May 2019 13:32
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to...
24 April 2019 15:50
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug...
28 March 2019 08:35
(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.
20 March 2019 10:33
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a...
25 February 2019 10:39
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application...
10 January 2019 11:26
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Thursday that the US Patent and Trademark Office (USPTO) has granted a second US patent for its 'Chronocort' modified...
17 October 2018 12:10
(Sharecast News) - Speciality pharmaceutical company Diurnal has put all development activities for its modified release hydrocortisone product on hold after it failed to meet its primary endpoint in a...
8 October 2018 09:29
(Sharecast News) - Clinical trials of Diurnal Group's Chronocort drug failed to meet the primary objective of proving superior to conventional therapy in endocrine control over a 24-hour period.
5 October 2018 09:20
(Sharecast News) - Specialist pharmaceutical company Diurnal said it had enrolled the first two patients in its US-based Chronocort phase III trial for adults with congenital adrenal hyperplasia (CAH).
15 May 2018 09:16
(Sharecast News) - Pharmaceutical firm Diurnal announced on Tuesday that it has launched its Alkindi product in Germany following the grant of European marketing authorisation in February.
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see http://www.DigitalLook.com/newsfeedterms for our terms and conditions.
© Digital Look Ltd 1998-2019. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.